11-Oct-2019 | Zion Market Research
Zion Market Research has published a new report titled “Recombinant Vaccines Market By Product (Attenuated, Vector, and Subunit), By Application (Veterinary and Human), By Disease (Hepatitis B, Cancer, Influenza, and Others), and By Distribution Channel (Hospitals, Clinics, Veterinary Clinics, Retail Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global recombinant vaccines market was USD 1,096 million in 2018 and is expected to generate around USD 1,685 million by 2025, at a CAGR of around 6.5% between 2019 and 2025.
Recombinant DNA molecules are prepared by genetic recombination methods to link genetic material from various sources. This method creates unique sequences that are not normally found in a genome. A vaccine is a formulation of weakened or killed microorganisms administered to a person for disease prevention. A recombinant vaccine is manufactured by introducing DNA (Deoxyribonucleic Acid) that is encoded in an antigen to trigger an immune reaction. Subunit recombinant vaccines attenuated recombinant vaccines, and vector recombinant vaccines are the three major recombinant vaccines types.
Browse the full “Recombinant Vaccines Market By Product (Attenuated, Vector, and Subunit), By Application (Veterinary and Human), By Disease (Hepatitis B, Cancer, Influenza, and Others), and By Distribution Channel (Hospitals, Clinics, Veterinary Clinics, Retail Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/recombinant-vaccines-market
The safe to use nature of recombinant vaccines, high investments by recombinant vaccine manufacturers for novel products’ development, rising government initiatives to boost the recombinant vaccines usage, increasing augmented and viable healthcare demand, simplified applications of recombinant vaccines, and growing accessibility of recombinant vaccines via conventional supply chains, escalating number of regulatory authorizations, and growing infectious diseases occurrence are driving the recombinant vaccines market globally. The rising awareness regarding recombinant vaccines benefits in developing regions, increasing per capita healthcare expenditure, growing demand for veterinary recombinant vaccines, and ongoing technological improvements in recombinant vaccines will create additional opportunities for the recombinant vaccines market in the years ahead. However, risks related to the use of attenuated vaccines, high cost of recombinant vaccines, and the lack of appropriate healthcare setup and trained physicians in developing regions will restrict the global recombinant vaccines market development.
The recombinant vaccines market is split based on type, application, disease, and distribution channel. Based on type, the recombinant vaccines market includes attenuated, vector, and subunit. The subunit segment accounted for the highest market share in 2018. The application segment includes veterinary and human. The human segment accounted for the highest market share in 2018. The disease segment comprises hepatitis B, cancer, influenza, and others. The hepatitis B segment is expected to register the highest CAGR over the estimated time period. The distribution channel segment is fragmented into hospitals, clinics, veterinary clinics, retail pharmacies, and others.
North America will lead the global recombinant vaccines market in the future, owing to rising developments in the field of genetic engineering and molecular biology, increasing transmittable diseases prevalence, huge research and development expenditure by major manufacturers, high vaccination rates, and rapid uptake of techniques like rDNA technology. Europe will hold the second spot in this global market, due to the presence of the latest treatment facilities, high healthcare expenditure, rising infectious disorders incidences, escalating cancer rate, and growing availability of latest healthcare infrastructure. The Asia Pacific will grow rapidly over the forecast period, owing to the rising government initiatives governments to increase vaccination rate, an enormous patient pool, increasing investments by domestic and global manufacturers, escalating the need for large quantities of vaccines, and ongoing R&D.
Some key players of the global recombinant vaccines market are Pfizer, Merck, Sanofi Pasteur, Bayer, GlaxoSmithKline, Serum Institute of India, Abiomed, Johnson & Johnson, Emergent Bio Solutions, and Mitsubishi Tanabe Pharma.
This report segments the global recombinant vaccines market as follows:
Global Recombinant Vaccines Market: By Type
Global Recombinant Vaccines Market: By Application
Global Recombinant Vaccines Market: By Disease
Global Recombinant Vaccines Market: By Distribution Channel
Global Recombinant Vaccines Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651